Latest

MDD

·July 7, 2020·4 min read

Brain Structural Elements in Psychiatric Disorders

Comparing data from multiple neuroimaging studies, researchers found shared brain structural abnormalities between four psychiatric disorders, including schizophrenia and bipolar disorder. They also identified brain signatures unique to each condition.

Featured Neuroscience Psychology

·June 16, 2020·2 min read

The molecular mechanisms of depression

Study reveals how the brain's opioid system is linked to mood changes associated with depression and anxiety. Neuroimaging revealed, in those with depression, there is a decreased number of opioid receptors in specific areas of the brain.

Featured Genetics Neuroscience Psychology

·June 11, 2020·3 min read

Adult stem cell study shows fish oil may help with depression

Using patient-derived adult stem cells, researchers found fish oil created an antidepressant response.

Featured Neuroscience Psychology

·April 23, 2020·5 min read

Natural mood regulation low or even absent in people with depression

During periods where personal choices of activities are constrained, natural mood regulation becomes impaired, resulting in an increased risk of depression.

Featured Neuroscience Open Neuroscience Articles Psychology

·March 20, 2020·3 min read

New drug can ease the side effects of medication against severe depression

A new substance named Lu AF60097 may help reduce side effects from tricyclic antidepressants in those with severe depression.

Featured Genetics Neuroscience Open Neuroscience Articles Psychology

·March 9, 2020·7 min read

The largest genetic map of psychiatric disorders so far

The largest genetic map of mental health disorders to date reveals there are three groups of highly genetically related disorders among eight psychiatric disorders. A gene related to nervous system development is a risk factor for all eight disorders studied. The RBFOX1 gene is implicated in seven of the eight disorders. ADHD and depression share 44% of genetic risk factors common in the general population. 109 pleiotropic loci affect more than one disorder. These pleiotropic loci are within genes that show heightened expression in the brain through the lifespan, beginning during the second trimester of pregnancy.

Featured Neuroscience Psychology

·February 20, 2020·6 min read

Decision time predicts the risk of depression relapse

Findings reveal it is possible to predict the risk of a person with MDD lapsing back into depression after stopping antidepressants. Those who relapse take longer to decide how much effort to invest for a reward.

Featured Neuroscience Open Neuroscience Articles Psychology

·February 7, 2020·4 min read

New biochemical ‘warning sign’ of early-stage depression identified

High levels of anthranilic acid in the blood may be a new biomarker for assessing the risk of developing major depressive disorder.

Featured Neuroscience Open Neuroscience Articles Psychology

·December 26, 2019·7 min read

Early-life exposure to dogs may lessen risk of developing schizophrenia

Exposure to household pet dogs in the early years of life was associated with a significantly decreased risk of being diagnosed with schizophrenia later in life.

This shows a depressed looking woman sitting by a christmas tree

Featured Neuroscience Open Neuroscience Articles Psychology

·December 16, 2019·5 min read

Want to avoid the holiday blues? Skip the sweet treats

If you are prone to depression, a new study suggests you should avoid indulging on dietary sugars. Added sugars have a pro-inflammatory effect on depressive disorders.

This is a diagram from one of the studies

Featured Neuroscience Psychology

·December 3, 2019·4 min read

Imaging reveals pathways behind depression

Two new neuroimaging studies shed light on structural and functional abnormalities in the brains of those with major depressive disorder.

Featured Neuroscience Neuroscience Videos Psychology

·November 18, 2019·4 min read

Side effects mild and brief with single antidepressant dose of intravenous ketamine

The side effects of administering ketamine to treat major depressive disorder are mild and persist for no longer than four hours, researchers report. Most of the side effects peaked within an hour of treatment, and many patients reported the effects as being significantly reduced two hours post ketamine administration.